KRAS and neoplasm: Jeason et al. studied the efficacy of ICIs in tumor samples from NSCLC patients harboring G12A, G12C, G12D, G12V or G13C KRAS mutations, and found no differences in progression-free survival (PFS) or OS between these major KRAS mutation subtypes [30].